Compare VABK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | TNXP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 194.9M |
| IPO Year | N/A | N/A |
| Metric | VABK | TNXP |
|---|---|---|
| Price | $39.46 | $15.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 8.7K | ★ 492.0K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 14.22 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $56,512,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | N/A | $750.19 |
| P/E Ratio | $12.33 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $33.66 | $6.76 |
| 52 Week High | $44.57 | $69.97 |
| Indicator | VABK | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 38.11 |
| Support Level | $39.00 | $14.94 |
| Resistance Level | $40.59 | $15.68 |
| Average True Range (ATR) | 0.78 | 0.87 |
| MACD | -0.23 | -0.15 |
| Stochastic Oscillator | 33.37 | 8.81 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.